Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt No Debt
ACRS's Cash-to-Debt is ranked higher than
65% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. ACRS: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
ACRS' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Interest Coverage No Debt
ACRS's Interest Coverage is ranked higher than
54% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ACRS: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ACRS' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 4
Altman Z-Score: 47.10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROE % -37.03
ACRS's ROE % is ranked lower than
52% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. ACRS: -37.03 )
Ranked among companies with meaningful ROE % only.
ACRS' s ROE % Range Over the Past 10 Years
Min: -64.46  Med: -50.58 Max: -36.7
Current: -37.03
-64.46
-36.7
ROA % -35.34
ACRS's ROA % is ranked lower than
57% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. ACRS: -35.34 )
Ranked among companies with meaningful ROA % only.
ACRS' s ROA % Range Over the Past 10 Years
Min: -53.93  Med: -36.88 Max: -35.34
Current: -35.34
-53.93
-35.34
ROC (Joel Greenblatt) % -8388.08
ACRS's ROC (Joel Greenblatt) % is ranked lower than
86% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. ACRS: -8388.08 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ACRS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -27668.42  Med: -7273.25 Max: -3195.88
Current: -8388.08
-27668.42
-3195.88
GuruFocus has detected 1 Warning Sign with Aclaris Therapeutics Inc $ACRS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ACRS's 30-Y Financials

Financials (Next Earnings Date: 2017-11-08 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

ACRS Guru Trades in

Q4 2016

ACRS Guru Trades in Q4 2016

Jim Simons 174,600 sh (New)
» More
Q1 2017

ACRS Guru Trades in Q1 2017

Steven Cohen 459,916 sh (New)
Louis Moore Bacon 62,500 sh (New)
Jim Simons 88,079 sh (-49.55%)
» More
Q2 2017

ACRS Guru Trades in Q2 2017

Steven Cohen 862,402 sh (+87.51%)
Louis Moore Bacon 50,000 sh (-20.00%)
Jim Simons 28,900 sh (-67.19%)
» More
» Details

Insider Trades

Latest Guru Trades with ACRS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:ALDR, NAS:BOLD, NAS:ABEO, NAS:AMAG, NAS:PRTK, NAS:AKAO, NAS:LJPC, NAS:DOVA, NAS:INSY, NAS:CHRS, NAS:RXDX, NAS:VSAR, NAS:ANAB, NAS:GTHX, NAS:MGNX, NAS:CTMX, NAS:RVNC, NAS:CYTK, NAS:IMGN, NAS:KALA » details
Traded in other countries:8AT.Germany,
Headquarter Location:USA
Aclaris Therapeutics Inc is a clinical-stage specialty pharmaceutical company which focuses on identifying, developing and commercializing differentiated drugs to address significant unmet needs in dermatology.

Aclaris Therapeutics Inc is a clinical-stage specialty pharmaceutical company which operates in United States. It focuses on identifying, developing and commercializing differentiated drugs to address significant unmet needs in dermatology. The company holds a drug candidate, A-101 Topical Solution which is a proprietary high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis (SK) a common non-malignant skin tumor. Its pipeline of drug candidates includes A-101 as a Topical Solution for treatment of SK, common warts; A-102 as a gel dosage form for treatment of SK and warts and A-201 and A-301 as an oral and topical formulation for treatment of autoimmune dermatologic respectively.

Ratios

vs
industry
vs
history
PB Ratio 4.09
ACRS's PB Ratio is ranked lower than
54% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. ACRS: 4.09 )
Ranked among companies with meaningful PB Ratio only.
ACRS' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 8.29
Current: 4.09
0
8.29
EV-to-EBIT -10.27
ACRS's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. ACRS: -10.27 )
Ranked among companies with meaningful EV-to-EBIT only.
ACRS' s EV-to-EBIT Range Over the Past 10 Years
Min: -17.53  Med: 0 Max: 0
Current: -10.27
-17.53
0
EV-to-EBITDA -10.31
ACRS's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. ACRS: -10.31 )
Ranked among companies with meaningful EV-to-EBITDA only.
ACRS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -17.58  Med: 0 Max: 0
Current: -10.31
-17.58
0
Current Ratio 21.00
ACRS's Current Ratio is ranked higher than
97% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. ACRS: 21.00 )
Ranked among companies with meaningful Current Ratio only.
ACRS' s Current Ratio Range Over the Past 10 Years
Min: 7.33  Med: 21 Max: 55.64
Current: 21
7.33
55.64
Quick Ratio 21.00
ACRS's Quick Ratio is ranked higher than
97% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. ACRS: 21.00 )
Ranked among companies with meaningful Quick Ratio only.
ACRS' s Quick Ratio Range Over the Past 10 Years
Min: 7.33  Med: 21 Max: 55.64
Current: 21
7.33
55.64

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 4.27
ACRS's Price-to-Net-Cash is ranked higher than
66% of the 530 Companies
in the Global Biotechnology industry.

( Industry Median: 7.61 vs. ACRS: 4.27 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ACRS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 4.13  Med: 5.28 Max: 6.94
Current: 4.27
4.13
6.94
Price-to-Net-Current-Asset-Value 4.14
ACRS's Price-to-Net-Current-Asset-Value is ranked higher than
65% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. ACRS: 4.14 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ACRS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 4  Med: 5.14 Max: 6.81
Current: 4.14
4
6.81
Price-to-Tangible-Book 4.11
ACRS's Price-to-Tangible-Book is ranked higher than
54% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. ACRS: 4.11 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ACRS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.97  Med: 4.59 Max: 6.76
Current: 4.11
3.97
6.76
Earnings Yield (Greenblatt) % -9.74
ACRS's Earnings Yield (Greenblatt) % is ranked lower than
51% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. ACRS: -9.74 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ACRS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -11.55  Med: 0 Max: 348.19
Current: -9.74
-11.55
348.19

More Statistics

EPS (TTM) $ -2.03
Short Percentage of Float16.30%
52-Week Range $20.15 - 33.25
Shares Outstanding (Mil)26.74

Analyst Estimate

Dec17 Dec18
Revenue (Mil $)
EPS ($) -3.07 -3.60
EPS without NRI ($) -3.07 -3.60
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}